Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.
Published September 2, 2020 · Recall initiated: August 14, 2020
Summary
FDA records drug Class II recall D-1533-2020, published September 2, 2020 and initiated August 14, 2020. Recalling firm: Hikma Pharmaceuticals USA Inc.; Status: Terminated; Reported quantity: 97,890 vials; Lot: Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
What to do
Voluntary: Firm initiated · Letter
Get an email if BUPRENORPHINE HYDROCHLORIDE has another recall
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Brand
- BUPRENORPHINE HYDROCHLORIDE
- Manufacturer
- Hikma Pharmaceuticals USA Inc.
- Distributor
- Nationwide in the U.S.
- Lot
- Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDABuprenorphine Hydrochloride, Injection 0.3 mg/mL, Rx Only, 5 x 1 mL Single Dose Vials, Manufactured for: EndoOctober 7, 2026
- FDABuprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, ForJune 24, 2026
- FDABuprenorphine Hydrochloride, Injection, 0.3mg/mL, 5x1 mL Single Dose Vials, Rx only, Manufactured for: EndoMay 20, 2026
- FDABuprenorphine Hydrochloride Injection, 0.3 mg base/mL, 1 mL Single-dose Carpuject, Sterile Cartridge Unit withJuly 3, 2024
- FDAChlorhexidine Gluconate 0012 For Manufacturing, Processing or Repacking, RX Only, Medichem, S.A. PoligonoSeptember 2, 2020
- FDAAlaris Syringe Module Model 8110 - Product Usage: is intended to provide trained healthcare caregivers a wayAugust 26, 2020
Questions about this recall
Was Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01. recalled?
Yes. FDA published recall D-1533-2020 on September 2, 2020. Reported hazard: Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.
What should I do if I have this product?
Voluntary: Firm initiated · Letter
How do I know if my unit is part of the recall?
Compare your product details with the notice. Brand: BUPRENORPHINE HYDROCHLORIDE.